A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants
Phase 1
Completed
NCT06262477
| Condition | Healthy Volunteer |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Biogen |
|---|
| Status | Completed |
|---|
| Enrollment | 300 participants |
|---|
| Interventions | BIIB800, Actemra |
|---|
| Start date | Jan 2, 2024 |
|---|
| Completion date | Sep 25, 2024 |
|---|
| Results posted | Oct 6, 2025 |
|---|
Summary
The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra.
Maximum Observed Serum Concentration (Cmax) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · micrograms per milliter (μg/mL)
| BIIB800 | 10.5 ± 43.3 micrograms per milliter (μg/mL) |
|---|
| Actemra | 10.0 ± 41.3 micrograms per milliter (μg/mL) |
|---|
| Ratio of GLSM | 1.05 (95% CI 0.974–1.13) |
|---|
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · hours (h)*μg/ mL
| BIIB800 | 2380 ± 44.9 hours (h)*μg/ mL |
|---|
| Actemra | 2240 ± 41.1 hours (h)*μg/ mL |
|---|
| Ratio of GLSM | 1.07 (95% CI 0.988–1.15) |
|---|
Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57) · h*μg/ mL
| BIIB800 | 2120 ± 45.9 h*μg/ mL |
|---|
| Actemra | 2000 ± 44.0 h*μg/ mL |
|---|
| Ratio of GLSM | 1.06 (95% CI 0.985–1.15) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.